Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relacorilant - Corcept Therapeutics

Drug Profile

Relacorilant - Corcept Therapeutics

Alternative Names: CORT-125134

Latest Information Update: 20 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Corcept Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Cushing syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cushing syndrome
  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase I/II Solid tumours
  • Phase I Prostate cancer

Most Recent Events

  • 20 Feb 2020 Corcept Therapeutics plans a phase Ib trial of relacorilant combined with an immunotherapeutic agent for Adrenal cancer (Combination therapy, Metastatic disease, Inoperable/unresectable), in the second quarter of 2020
  • 30 Jan 2020 Corcept Therapeutics plans a phase III trial for Pancreatic cancer (Combination therapy, Metastatic disease) in USA in the second quarter of 2020
  • 07 Nov 2019 Corcept Therapeutics announces intention to submit NDA to the US FDA for Cushing syndrome in the fourth quarter of 2021
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top